CIA
VKTX icon

Concurrent Investment Advisors’s Viking Therapeutics VKTX Stock Holding History

Concurrent Investment Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.9M Sell
306,280
-41,506
-12% -$1.34M 0.1% 220
2026
Q1 		$11.3M Buy
347,786
+66,734
+24% +$2.14M 0.12% 180
2025
Q4 		$9.89M Buy
281,052
+264,750
+1,624% +$9.38M 0.11% 188
2025
Q3 		$428K Buy
16,302
+6,712
+70% +$200K 0.01% 980
2025
Q2 		$254K Buy
9,590
+488
+5% +$12.8K ﹤0.01% 1145
2025
Q1 		$220K Buy
+9,102
New +$288K 0.01% 1081

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Concurrent Investment Advisors's VKTX Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its Viking Therapeutics (VKTX) stake by 12% in Q2 2026, selling an estimated $1.34M and leaving 306,280 shares worth $11.9M. The position accounts for 0.1% of the portfolio, ranked #220.

Concurrent Investment Advisors first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Concurrent Investment Advisors held 306,280 shares of Viking Therapeutics worth $11.9M as of Q2 2026.
  • Concurrent Investment Advisors sold 41,506 Viking Therapeutics shares in Q2 2026, an estimated $1.34M.
  • Viking Therapeutics made up 0.1% of Concurrent Investment Advisors's portfolio in Q2 2026, its #220 holding.
  • Concurrent Investment Advisors first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.